|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | ||||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||||
| Depreciation and amortization | ||||
| Impairment of intangible assets | ||||
| Intangible assets impairment | ||||
| Impairment of goodwill | ||||
| Share-based compensation | ||||
| Payment-In-Kind (“PIK”) Interest | ||||
| Deferred income taxes | ||||
| Unrealized loss (gain) on equity securities | ||||
| Investment impairment | ||||
| Warrant expense | ||||
| Gain on troubled debt restructuring | ||||
| Net accretion of investments | ||||
| Loss on disposal of property, equipment, and capitalized software | ||||
| Gain on sale of California MA business | ||||
| Other, net | ||||
| Changes in assets and liabilities, net of acquired assets and liabilities: | ||||
| Accounts receivable | ||||
| Direct Contracting performance year receivable | ||||
| ACO REACH performance year receivable | ||||
| Other assets | ||||
| Medical cost payable | ||||
| Risk adjustment payable | ||||
| Accounts payable and other liabilities | ||||
| Unearned revenue | ||||
| Warrant liability | ||||
| Risk share payable to deconsolidated entity | ||||
| Net cash used in operating activities | ||||
| Cash flows from investing activities: | ||||
| Purchases of investments | ||||
| Proceeds from sales, paydowns, and maturities of investments | ||||
| Purchases of property and equipment | ||||
| Proceeds from sale of business, net | ||||
| Business acquisitions, net of cash acquired | ||||
| Net cash provided by investing activities | ||||
| Cash flows from financing activities: | ||||
| Proceeds from issuance of preferred stock | ||||
| Proceeds from issuance of common stock | ||||
| Proceeds from long-term borrowings | ||||
| Proceeds from short-term borrowings | ||||
| Repayments of short-term borrowings | ||||
| Payments for debt issuance costs | ||||
| Purchase of non-controlling interests | ||||
| Distribution to non-controlling interest holders | ||||
| Proceeds from IPO | ||||
| Payments for IPO offering costs | ||||
| Net cash (used in) provided by financing activities | ||||
| Net decrease in cash and cash equivalents | ||||
| Cash and cash equivalents of continuing and discontinued operations– beginning of year | ||||
| Cash and cash equivalents of continuing and discontinued operations– end of year | ||||
| Supplemental disclosures of cash flow information: | ||||
| Issuance of equity warrants | ||||
| Changes in unrealized gain (loss) on available-for-sale securities in OCI | ||||
| Cash paid for interest | ||||
| Redeemable convertible preferred stock issued for acquisitions | ||||
| Contingent consideration | ||||
| Conversion of redeemable convertible preferred stock to common stock upon initial public offering |
Loading...
